NO2493457T3 - - Google Patents

Info

Publication number
NO2493457T3
NO2493457T3 NO10827255A NO10827255A NO2493457T3 NO 2493457 T3 NO2493457 T3 NO 2493457T3 NO 10827255 A NO10827255 A NO 10827255A NO 10827255 A NO10827255 A NO 10827255A NO 2493457 T3 NO2493457 T3 NO 2493457T3
Authority
NO
Norway
Application number
NO10827255A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2493457T3 publication Critical patent/NO2493457T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO10827255A 2009-10-30 2010-10-26 NO2493457T3 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2009072216 2009-10-30
PCT/SG2010/000409 WO2011053251A1 (en) 2009-10-30 2010-10-26 Fast dissolving solid dosage form

Publications (1)

Publication Number Publication Date
NO2493457T3 true NO2493457T3 (ja) 2018-01-06

Family

ID=43922359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10827255A NO2493457T3 (ja) 2009-10-30 2010-10-26

Country Status (18)

Country Link
US (4) US10744086B2 (ja)
EP (3) EP3332772A1 (ja)
JP (1) JP5777170B2 (ja)
KR (1) KR101612073B1 (ja)
CN (2) CN107811980B (ja)
AU (1) AU2010313785C1 (ja)
CA (1) CA2777218C (ja)
DK (2) DK3254676T3 (ja)
ES (2) ES2641821T3 (ja)
HK (1) HK1251914A1 (ja)
MY (1) MY150626A (ja)
NO (1) NO2493457T3 (ja)
NZ (1) NZ599594A (ja)
PL (2) PL3254676T3 (ja)
SG (1) SG174465A1 (ja)
TR (1) TR201902233T4 (ja)
WO (1) WO2011053251A1 (ja)
ZA (1) ZA201400310B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) * 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
KR101612073B1 (ko) 2009-10-30 2016-04-14 아이엑스 바이오파마 리미티드 신속 용해 고체 투약 제형
JP6061859B2 (ja) * 2010-10-08 2017-01-18 アール．ピー． シェーラー テクノロジーズ エルエルシー デンプンを使用する経口ワクチン速溶性剤型
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
CN102784117A (zh) * 2012-08-23 2012-11-21 海南卫康制药(潜山)有限公司 硫酸庆大霉素组合物冻干口腔崩解片及其制备方法
JP2015533155A (ja) * 2012-10-11 2015-11-19 アイエックス バイオファーマ リミテッド 固体剤形
KR102007798B1 (ko) * 2013-05-30 2019-08-07 (주)아모레퍼시픽 발포정 정제 및 화장수를 포함하는 화장용 키트
US9456981B2 (en) * 2014-02-13 2016-10-04 Cadila Healthcare Limited Stable orally disintegrating tablets of hyoscyamine
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
ES2738652T3 (es) * 2015-07-16 2020-01-24 Swipp Ab Composiciones de midazolam para administración bucal en el tratamiento de convulsiones para obtener comienzo de acción rápido
CN109475508A (zh) * 2016-06-07 2019-03-15 阿瑞迪思医药品股份有限责任公司 具有增强的热稳定性的含有生物活性材料的速溶薄膜的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
CN109381448A (zh) * 2017-08-04 2019-02-26 广州朗圣药业有限公司 一种利伐沙班口腔速溶膜剂及其制备方法
EP3761970A4 (en) * 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
WO2019215862A1 (ja) * 2018-05-10 2019-11-14 救急薬品工業株式会社 シトクロムｐ４５０代謝活性の評価方法
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2019246074A1 (en) * 2018-06-18 2019-12-26 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
BR112021004053A2 (pt) * 2018-09-07 2021-05-25 Aquestive Therapeutics, Inc. composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos
EP3996695A4 (en) * 2019-08-12 2023-03-15 Tenshi Kaizen Private Limited CANNABIDIOL TABLETS DISSOLVING IN THE MOUTH
US20210308075A1 (en) * 2020-04-07 2021-10-07 Joseph Habboushe Prevention and treatment of virial infections
CN113633616A (zh) * 2020-05-11 2021-11-12 鲁南制药集团股份有限公司 一种生物利用度高的固体制剂
WO2021241898A1 (ko) * 2020-05-26 2021-12-02 주식회사 경보제약 동물에서의 기생충 감염 질환을 치료 또는 예방하기 위한 수의학적 구강붕해필름 제제
EP4157244A1 (en) * 2020-06-02 2023-04-05 IX Biopharma Limited Methods for treating major depressive disorder and treatment-resistant depression
CN113693999A (zh) * 2020-12-10 2021-11-26 洛里·安妮·玛丽·米亚斯 一种用于溶解到流体化妆品中的固态组合物和流体化妆品
CN113244183A (zh) * 2021-06-07 2021-08-13 河南合智医药科技有限公司 一种肌苷的口腔速溶片及其制备方法
US11793820B2 (en) * 2021-09-24 2023-10-24 Chadwick Donaldson Dry powder foamable formulations for delivery of medicaments through the mucosa

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2036890B1 (ja) * 1969-04-15 1973-01-12 Orsymonde
JPS4868726A (ja) * 1971-12-27 1973-09-19
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
DE4020144A1 (de) 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
RU2161954C2 (ru) * 1994-01-27 2001-01-20 Дзе Борд оф Регентс оф Дзе Юниверсити оф Оклахома Быстрорастворяющиеся во рту лекарственные формы
US5698217A (en) 1995-05-31 1997-12-16 Minnesota Mining And Manufacturing Company Transdermal drug delivery device containing a desiccant
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
JP4563516B2 (ja) 1997-02-20 2010-10-13 マサチューセッツ インスティテュート オブ テクノロジー 迅速分散性を示す投与剤形、その使用法並びにその製造方法
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
GB9717770D0 (en) 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
HU228179B1 (en) 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
AU2007203233B2 (en) 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
AU765526B2 (en) * 1999-08-17 2003-09-18 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
WO2001037814A1 (en) * 1999-11-23 2001-05-31 Robert Gordon University Bilayered buccal tablets comprising nicotine
DE19959913A1 (de) 1999-12-11 2001-06-28 Lohmann Therapie Syst Lts Acetylsalicylsäure enthaltendes transdermales System zur Behandlung von Migräne
JP2001278812A (ja) * 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
AU2001266956A1 (en) 2000-06-16 2002-01-02 Evaltec Personnel golfing assistant
US7118498B2 (en) 2000-06-16 2006-10-10 Skyhawke Technologies, Llc Personal golfing assistant and method and system for graphically displaying golf related information and for collection, processing and distribution of golf related data
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP4284017B2 (ja) 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
EP2332523B8 (en) 2001-10-12 2022-04-20 Aquestive Therapeutics, Inc. Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
CA2473967C (en) 2001-10-12 2011-06-14 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made therefrom
WO2003030881A1 (en) 2001-10-12 2003-04-17 Kosmos Pharma Glucan based film delivery systems
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20030224090A1 (en) * 2002-02-11 2003-12-04 Edizone, Lc Snacks of orally soluble edible films
US20040247649A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
DE10207394B4 (de) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
GB0226076D0 (en) 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
US20040156895A1 (en) 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
CA2514897C (en) 2003-01-30 2012-08-28 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
WO2004067004A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
MXPA05009079A (es) 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
JP4795962B2 (ja) 2003-05-28 2011-10-19 モノソル・アールエックス・エルエルシー ポリエチレンオキシドフィルムおよびそれからなる薬物送達系
JP4563393B2 (ja) * 2003-10-24 2010-10-13 アドヒーシブズ・リサーチ・インコーポレイテッド 診断デバイス用崩壊性フィルム
AU2005210637B2 (en) * 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
TWI342222B (en) 2004-03-08 2011-05-21 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of rapidly dissolving tablet and method of fabricating the same
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
EP1621186A1 (en) * 2004-07-29 2006-02-01 Cephalon France Modafinil oral lyophilizate
JP5160229B2 (ja) 2004-09-30 2013-03-13 モノソル・アールエックス・エルエルシー 均一の成分を有する多層フィルム
RU2007133503A (ru) 2005-02-10 2009-03-20 Орексо Аб (Se) Новые фармацевтические композиции, пригодные для трансмукозального введения лекарств
US20060207911A1 (en) * 2005-03-15 2006-09-21 Bullock John D Emergency medical treatment system
JP2008534564A (ja) 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 痛みの治療に有用な新しい製薬組成物
DE102005015128B4 (de) 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
CN101166531A (zh) 2005-04-20 2008-04-23 日绊株式会社 经皮吸收制剂
WO2007002125A1 (en) 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
KR20130016386A (ko) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CA2621263A1 (en) 2005-09-09 2007-03-15 Garry L. Myers Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP1937414A4 (en) * 2005-09-19 2013-01-02 Univ Witwatersrand Jhb PHARMACEUTICAL FORM FOR ORAL MUCOUSES
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP2009518405A (ja) 2005-12-06 2009-05-07 モノソル アールエックス リミテッド ライアビリティ カンパニー 活性物質の送達のための局所フィルム組成物
WO2007075422A2 (en) 2005-12-27 2007-07-05 Monosol Rx, Llc Ph modulated films for delivery of actives
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2101740B1 (en) 2006-12-04 2013-11-06 Orexo AB New non-abusable pharmaceutical composition comprising opioids
US20080220029A1 (en) * 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
CN101084891A (zh) 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
US20090047350A1 (en) 2007-08-17 2009-02-19 Ramesh Bangalore Perforated water soluble polymer based edible films
WO2009045022A2 (en) 2007-10-03 2009-04-09 C.L. Pharm Edible film
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
DE102008014533A1 (de) 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival-Wafer
CN101332197B (zh) * 2008-03-25 2010-12-08 江苏奥赛康药业有限公司 盐酸洛哌丁胺二甲硅油复方口腔速溶膜
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
CN101981059B (zh) * 2008-03-31 2014-08-20 旭化成化学株式会社 具有出色的崩解性能的经加工的淀粉粉末及其制造方法
JP5122380B2 (ja) * 2008-06-16 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 薬物の放出を制御した速崩錠及びその製法
AU2009269958A1 (en) 2008-07-11 2010-01-14 Ix Biopharma Pte Ltd Opioid agonist compositions for pain management
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2403482B1 (en) 2009-03-04 2017-12-27 Emplicure AB Abuse resistant formulation
ES2673196T3 (es) 2009-05-08 2018-06-20 Emplicure Ab Composición para la administración sostenida de fármacos que comprende aglutinante geopolimérico
KR101612073B1 (ko) 2009-10-30 2016-04-14 아이엑스 바이오파마 리미티드 신속 용해 고체 투약 제형
US20220347095A1 (en) 2009-10-30 2022-11-03 Ix Biopharma Ltd Solid Dosage Form
DK2515886T3 (en) 2009-12-22 2018-06-14 Luye Pharma Ag Transdermal therapeutic system for administration of rivastigmine or derivatives thereof
EP2549988A1 (en) 2010-03-23 2013-01-30 Apr Applied Pharma Research S.A. Fast dissolving drug delivery systems
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
SG187158A1 (en) 2010-07-21 2013-02-28 3M Innovative Properties Co Transdermal adhesive compositions, devices, and methods
JP2012051875A (ja) 2010-08-03 2012-03-15 Hisamitsu Pharmaceut Co Inc 経皮・経粘膜吸収製剤の保存方法及び経皮・経粘膜吸収製剤包装体
FR2967066B1 (fr) 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
AU2012307530B2 (en) 2011-09-16 2016-12-08 Ferring B.V. A fast dissolving pharmaceutical composition
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
CN104136025B (zh) 2012-02-28 2017-10-24 日绊株式会社 贴附剂
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases

Also Published As

Publication number Publication date
EP3332772A1 (en) 2018-06-13
PL2493457T3 (pl) 2018-01-31
KR20120102585A (ko) 2012-09-18
ES2641821T3 (es) 2017-11-14
DK2493457T3 (en) 2017-10-02
EP3254676B1 (en) 2018-11-28
EP2493457A4 (en) 2013-07-03
US20200046637A1 (en) 2020-02-13
ES2712989T3 (es) 2019-05-17
AU2010313785A1 (en) 2011-09-08
AU2010313785B2 (en) 2012-11-08
US20140178473A1 (en) 2014-06-26
EP2493457B1 (en) 2017-08-09
CA2777218C (en) 2016-09-27
JP5777170B2 (ja) 2015-09-09
DK3254676T3 (en) 2019-03-11
CN102933207B (zh) 2018-02-02
US11975097B2 (en) 2024-05-07
WO2011053251A1 (en) 2011-05-05
NZ599594A (en) 2014-06-27
CA2777218A1 (en) 2011-05-05
PL3254676T3 (pl) 2019-06-28
US20230086496A1 (en) 2023-03-23
JP2013509403A (ja) 2013-03-14
CN107811980A (zh) 2018-03-20
US10744086B2 (en) 2020-08-18
KR101612073B1 (ko) 2016-04-14
CN102933207A (zh) 2013-02-13
EP3254676A1 (en) 2017-12-13
EP2493457A1 (en) 2012-09-05
HK1251914A1 (zh) 2019-05-03
AU2010313785C1 (en) 2019-04-11
ZA201400310B (en) 2015-12-23
MY150626A (en) 2014-02-07
US20120219628A1 (en) 2012-08-30
US10857097B2 (en) 2020-12-08
SG174465A1 (en) 2011-10-28
CN107811980B (zh) 2021-06-18
TR201902233T4 (tr) 2019-03-21

Similar Documents

Publication Publication Date Title
BR112012008267A2 (ja)
BR112012003062A2 (ja)
BR112012008195A2 (ja)
BR112012000607A2 (ja)
BRPI0925311A2 (ja)
BRPI0924307A2 (ja)
BR112012000665A2 (ja)
BR112012003853A2 (ja)
BR112012012080A2 (ja)
BR112012009797A2 (ja)
BR112012009446A2 (ja)
BR112012009703A2 (ja)
NO2493457T3 (ja)
BR112012010357A2 (ja)
BR112012007656A2 (ja)
BR112012002627A2 (ja)
BR112012001263A2 (ja)
BR112012000159A2 (ja)
BRPI0924534A2 (ja)
BR112012007654A2 (ja)
BR112012005951A2 (ja)
BR112012000255A2 (ja)
BR112012000156A2 (ja)
BRPI0924617A2 (ja)
BR112012009404A2 (ja)